^
    Back
    Association details:
    Biomarker:PIK3CA H1047R + PIK3C2B amplification
    Cancer:Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    JCO Precis Oncol
    Title:

    Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib

    Excerpt:
    A 55-year-old woman presented with a large breast ulceration, biopsy specimen–diagnosed invasive ductal carcinoma (IDC), grade 3, ER+/PR+/HER2−…Tumor sequencing showed an activating PIK3CA mutation H1047R and amplification of PIK3C2B. Disease progressed after 4 months of treatment with fulvestrant and palbociclib.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1200/PO.19.00403